EP Patent

EP3970730A1 — System for use and monitoring of inhaled nitric oxide with left ventricular assist devices

Assigned to Mallinckrodt Pharmaceuticals Ireland Ltd · Expires 2022-03-23 · 4y expired

What this patent protects

A system for determining whether a patient with pulmonary hypertension will resolve the pulmonary hypertension with continued use of a left ventricular assist device (LVAD), comprises:a means for measuring one or more pulmonary hemodynamic parameters of a patient with an LVAD to …

USPTO Abstract

A system for determining whether a patient with pulmonary hypertension will resolve the pulmonary hypertension with continued use of a left ventricular assist device (LVAD), comprises:a means for measuring one or more pulmonary hemodynamic parameters of a patient with an LVAD to obtain a first pulmonary hemodynamic value;a nitric oxide delivery device configured for, after obtaining the first pulmonary hemodynamic value, administering inhaled nitric oxide to the patient with the LVAD; anda means for measuring one or more pulmonary hemodynamic parameters of the patient during or after the inhaled nitric oxide administration to obtain a second pulmonary hemodynamic value,wherein the nitric oxide delivery device is configured for adjusting the inhaled nitric oxide based on a comparison of the second pulmonary hemodynamic value to a predetermined range, andwherein the pulmonary hemodynamic parameter is selected from left atrial pressure and pulmonary capillary wedge pressure;wherein an increase in left atrial pressure and/or pulmonary capillary wedge pressure from the first pulmonary hemodynamic value to the second pulmonary hemodynamic value of less than 5 mm Hg is indicative of improvement.

Drugs covered by this patent

Patent Metadata

Patent number
EP3970730A1
Jurisdiction
EP
Classification
Expires
2022-03-23
Drug substance claim
No
Drug product claim
No
Assignee
Mallinckrodt Pharmaceuticals Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.